Why the study?
Does the addition of domperidone to bromocriptine prevent nausea and vomiting and allow for clinical improvement in patients with idiopathic Parkinson disease?
Does the addition of domperidone to bromocriptine prevent nausea and vomiting and allow for clinical improvement in patients with idiopathic Parkinson disease?
Domperidone effectively prevents bromocriptine-induced nausea and vomiting in Parkinson's disease, allowing for rapid dose escalation and significant clinical improvement.
Answers are grounded in this paper and cite their sources.
May enable higher bromocriptine doses without nausea in Parkinson disease; leaves open need for randomized confirmation of benefit and safety.
In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects. Combination of the two drugs permitted rapid increase in bromocriptine dosage from 22.5 mg per day to 148 mg per day, with 71% mean clinical improvement over baseline score; continuing efficacy of the regimen was evident for a mean follow-up of 2 months.
No takes yet. Share an insight, caveat, or question.
Quinn et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: